Scientific Publications

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL),

American Society of Hematology Annual Meeting, Ghobadi et al, December 2023

Science Translational Medicine, Berrien-Elliot et al, February 2022

Clin Cancer Res, Marin et al, June 2021

Cancer Discovery, Berrien-Elliott et al, December 2020

Blood, Gang et al, November 2020

Seminars in Hematology, Gang et al, November 2020

Best Practice & Research Clinical Haematology, Cooper and DiPersio, December 2019

Leukemia, Cooper et al, February 2018

Biol Blood Marrow Transplant, Wagner et al, March 2017

Science Translational Medicine, Romee et al, September 2016

Biol Blood Marrow Transplant, Leong et al, April 2014

Blood, Romee et al, December 2012

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic …

ST. LOUIS, MO and SAN DIEGO, CA, Feb. 26, 2025 – Wugen, Inc., a clinical-stage U.S. …

— Data Support Start of First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell …

4260 Forest Park Ave
Suite 100
St. Louis, MO 63108
(636) 385-5306

9880 Campus Point Dr
Suite 430
San Diego, CA 92121